Indication

PD-L1 positive, EGFR-negative, ALK-negative, ROS1-negative non-small cell lung cancer

PD-L1 positive, EGFR-negative, ALK-negative, ROS1-negative non-small cell lung cancer is a clinically defined molecular subgroup of epithelial malignancies of the respiratory system. Read more about PD-L1 positive, EGFR-negative, ALK-negative, ROS1-negative non-small cell lung cancer

1 drugs 1 manufacturers

Drugs that treat it

Common PD-L1 positive, EGFR-negative, ALK-negative, ROS1-negative non-small cell lung cancer therapies.

Showing 1–1 of 1 drugs

Sort

LIBTAYO (cemiplimab-rwlc)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·BASAL CELL CARCINOMA OF SKIN·+3

Regeneron Pharmaceuticals, Inc.

News & literature

Coming soon

Related codes

Coming soon

About PD-L1 positive, EGFR-negative, ALK-negative, ROS1-negative non-small cell lung cancer.

PD-L1 positive, EGFR-negative, ALK-negative, ROS1-negative non-small cell lung cancer is a clinically defined molecular subgroup of epithelial malignancies of the respiratory system.

It is characterized by immunohistochemical expression of programmed death-ligand 1 (PD-L1) on tumor or immune cells alongside the documented absence of targetable driver alterations in the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1) genes.

Pathophysiologically, elevated PD-L1 promotes tumor immune evasion by binding PD-1 receptors on T cells to suppress antitumor immunity, while the wild-type status of EGFR, ALK, and ROS1 indicates the disease lacks key oncogenic receptor tyrosine kinase addictions.

This distinct biomarker profile identifies patients who are ineligible for standard frontline targeted tyrosine kinase inhibitors but exhibit heightened biological susceptibility to immune checkpoint inhibitor therapies.

onclive.com
PD-L1 positive, EGFR-negative, ALK-negative, ROS1-negative non-small cell lung cancer is a clinically defined molecular subgroup of epithelial malignancies of the respiratory system It is characterized by immunohistochemical expression of programmed death-ligand 1 (PD-L1) on tumor or immune cells alongside the documented absence of targetable driver alterations in the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1) genes
nih.gov
PD-L1 positive, EGFR-negative, ALK-negative, ROS1-negative non-small cell lung cancer is a clinically defined molecular subgroup of epithelial malignancies of the respiratory system Pathophysiologically, elevated PD-L1 promotes tumor immune evasion by binding PD-1 receptors on T cells to suppress antitumor immunity, while the wild-type status of EGFR, ALK, and ROS1 indicates the disease lacks key oncogenic receptor tyrosine kinase addictions This distinct biomarker profile identifies patients wh...
nih.gov
It is characterized by immunohistochemical expression of programmed death-ligand 1 (PD-L1) on tumor or immune cells alongside the documented absence of targetable driver alterations in the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1) genes
nih.gov
Pathophysiologically, elevated PD-L1 promotes tumor immune evasion by binding PD-1 receptors on T cells to suppress antitumor immunity, while the wild-type status of EGFR, ALK, and ROS1 indicates the disease lacks key oncogenic receptor tyrosine kinase addictions
researchgate.net
Pathophysiologically, elevated PD-L1 promotes tumor immune evasion by binding PD-1 receptors on T cells to suppress antitumor immunity, while the wild-type status of EGFR, ALK, and ROS1 indicates the disease lacks key oncogenic receptor tyrosine kinase addictions
ajmc.com
This distinct biomarker profile identifies patients who are ineligible for standard frontline targeted tyrosine kinase inhibitors but exhibit heightened biological susceptibility to immune checkpoint inhibitor therapies

Personalize your experience

Follow PD-L1 positive, EGFR-negative, ALK-negative, ROS1-negative non-small cell lung cancer and get updates as they land.

Create a free account

Already a member? Sign in

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it